BioAtla Announces Key Presentation at Notable Cancer Meeting
BioAtla, Inc. (NASDAQ: BCAB), a pioneering player in clinical-stage biotechnology, is set to showcase its advancements in the field of cancer therapeutics at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting. This significant event, which runs from November 8 to November 10, 2024, will take place at the George R. Brown Convention Center.
Presentation Overview
The poster presentation will feature updated findings from a pivotal phase 1 study investigating evalstotug (BA3071), a cutting-edge anti-CTLA-4 conditionally active biologic. This promising therapy has been evaluated both independently and in conjunction with nivolumab, targeting advanced solid tumors.
Details of the Presentation
The presentation will delve into the following key details:
- Title: Updated results from a phase 1 study of evalstotug (BA3071)
- Authors: Jacob Thomas, Eva Selfridge, Costantine Albany among others
- Abstract Number: 497
- Date & Time: November 8, 2024, at 9:00 AM CDT
- Location: Exhibit Halls AB
About BioAtla and Its Innovations
BioAtla stands out as a global leader in biotechnology, focusing intently on the innovative development of Conditionally Active Biologics (CAB). This groundbreaking approach allows the formulation of highly selective and efficient biopharmaceutical products designed to treat solid tumors while minimizing systemic toxicity.
Technological Advancements
By employing proprietary technology, BioAtla creates biologics that are not only effective but also more cost-efficient than traditional antibodies. The company's CAB candidates are continuously demonstrating improved safety profiles, making them suitable for combination therapies with other immune checkpoint inhibitors.
Regulatory and Clinical Progress
BioAtla has a robust pipeline, including two first-in-class CAB programs currently in Phase 2 clinical testing. These include:
- Mecbotamab vedotin: An AXL-targeted antibody-drug conjugate designed to directly combat tumor malignancies.
- Ozuriftamab vedotin: A unique ROR2-targeted antibody-drug conjugate aimed at enhancing treatment responses in difficult-to-treat cancer types.
Furthermore, their dual CAB bispecific T-cell engager antibody, BA3182, is undergoing Phase 1 development, showcasing BioAtla's commitment to advancing cancer treatments.
Patent Coverage and Future Directions
With over 765 active patent matters, including 500 issued patents, BioAtla enjoys comprehensive patent protection across major global markets. This protection encompasses various methods of manufacturing and screening CAB therapies, ensuring a competitive edge in the biopharmaceutical landscape.
Connect with BioAtla
For further information about BioAtla and its pioneering research, interested parties can explore the company's official website. Engage with BioAtla's scientific developments and stay updated on innovative therapies shaping the future of cancer treatment.
Company Contacts
Internal Contact:
Richard Waldron
Chief Financial Officer
BioAtla, Inc.
Email: rwaldron@bioatla.com
Phone: 858.356.8945
External Contact:
Bruce Mackle
LifeSci Advisors, LLC
Email: bmackle@lifesciadvisors.com
Frequently Asked Questions
What is BioAtla's main focus?
BioAtla focuses on developing advanced biologic therapies for cancer treatment through its unique CAB technology.
What significant event is BioAtla participating in?
BioAtla is presenting at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.
What is evalstotug?
Evalstotug is an anti-CTLA-4 conditionally active biologic being studied for its effects on advanced solid tumors.
What clinical stages are BioAtla’s products currently in?
BioAtla has multiple products in various clinical stages, with significant ones in Phase 2 trials.
Where can I find more information about BioAtla?
You can find more information by visiting the official BioAtla website.
